Gilead Sciences, Inc. (GILD): Growth Prospects Backed by Analyst Upgrades

Gilead Sciences Inc. (NASDAQ:GILD) is one of Goldman Sachs top healthcare stocks. On March 10, Jefferies initiated coverage of Gilead Sciences Inc. (NASDAQ:GILD) with a Buy rating and a $180 price target. The research firm has touted the company’s earnings-per-share growth and margin-expansion prospects as part of its bullish thesis.

Gilead Sciences, Inc. (GILD): Growth Prospects Backed by Analyst Upgrades

kurhan / shutterstock.com

According to the research firm, the company is not facing any near-term intellectual property cliffs or significant operating leverage. Instead, it is well positioned with its HIV franchise and the prospects for follow-on products. The research firm is also optimistic about the company’s prospects with the launch of Yetzugo in pre-exposure prophylaxis.

In addition, Gilead Sciences is making significant progress on its pipeline development. A phase 3 RAINIER trial for drug povetacicept has already met primary and secondary endpoints in treating immunoglobulin A nephropathy (IgAN).

Amid the pipeline development, Gilead has also inked a $7.8 billion deal to acquire blood cancer drug developer Arcellx. The deal follows a long partnership, signed in 2022, for the commercialization of medicines to combat multiple myeloma.

Gilead Sciences, Inc. (NASDAQ:GILD) is a US-based biopharmaceutical company that discovers, develops, and commercializes innovative medicines for life-threatening diseases, particularly in virology, oncology, and inflammation. It is known for its leadership in antiviral therapies for HIV, Hepatitis B and C, and COVID-19, with a strong focus on expanding its impact globally, including in Asia.

READ NEXT: 40 Most Popular Stocks Among Hedge Funds Heading Into 2026 and 11 Best Affordable Growth Stocks to Buy Now.

Disclosure: None. Follow Insider Monkey on Google News.